Abstract
J Hamilton currently serves as vice president of Clinical Development at Arrowhead Pharmaceuticals, Inc. (CA, USA), where he is responsible for clinical strategy, clinical trial design, implementation and execution. In this role, he managed the ARC-520, ARC-521 and ARC-AAT global programs. Previously, he was medical director and head of Corporate Development at Arrowhead. He led Arrowhead's acquisition of the Novartis RNAi assets and led Arrowhead's $670 million cardiovascular deal with Amgen (CA, USA). He earned an MD and MBA at The Ohio State University (USA) and is a licensed physician with board certification in emergency medicine. J Hamilton speaks to Hannah Makin, commissioning editor.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
